Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

This phase II trial evaluates the effect of azacitidine or decitabine and venetoclax in treating patients with acute myeloid leukemia that has not been treated before (treatment naive) or has come back (relapsed). Chemotherapy drugs, such as azacitidine, decitabine, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Trial Details

NCT ID
NCT04905810
Phase
PHASE2
Sponsor
Brian Jonas
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Azacitidine
  • Decitabine
  • Venetoclax
Locations (sample)
  • Clovis, California, United States|36.82523,-119.70292
  • Los Angeles, California, United States|34.05223,-118.24368
  • Sacramento, California, United States|38.58157,-121.4944
  • Oklahoma City, Oklahoma, United States|35.46756,-97.51643

Key Eligibility Criteria

  • Ability to understand and the willingness to sign a written informed consent
  • Diagnosis of AML by World Health Organization (WHO) 2016 criteria (Arber 2016)
  • Age \>= 18 years
  • Treatment naïve and eligible for venetoclax plus HMA: \* Age \>= 75 OR \* Age \>= 18-74 with at least one of the following co-morbidities: \*\* Eas…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →